JP2024546950A5 - - Google Patents

Info

Publication number
JP2024546950A5
JP2024546950A5 JP2024535950A JP2024535950A JP2024546950A5 JP 2024546950 A5 JP2024546950 A5 JP 2024546950A5 JP 2024535950 A JP2024535950 A JP 2024535950A JP 2024535950 A JP2024535950 A JP 2024535950A JP 2024546950 A5 JP2024546950 A5 JP 2024546950A5
Authority
JP
Japan
Prior art keywords
fluoroalkyl
branched
pharmaceutically acceptable
alkyl
tautomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024535950A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024546950A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/081714 external-priority patent/WO2023114944A1/en
Publication of JP2024546950A publication Critical patent/JP2024546950A/ja
Publication of JP2024546950A5 publication Critical patent/JP2024546950A5/ja
Pending legal-status Critical Current

Links

JP2024535950A 2021-12-16 2022-12-15 脂質ナノ粒子に用いるフッ化カチオン性脂質 Pending JP2024546950A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163290384P 2021-12-16 2021-12-16
US63/290,384 2021-12-16
PCT/US2022/081714 WO2023114944A1 (en) 2021-12-16 2022-12-15 Fluorinated cationic lipids for use in lipid nanoparticles

Publications (2)

Publication Number Publication Date
JP2024546950A JP2024546950A (ja) 2024-12-26
JP2024546950A5 true JP2024546950A5 (cg-RX-API-DMAC7.html) 2025-12-12

Family

ID=85108851

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024535950A Pending JP2024546950A (ja) 2021-12-16 2022-12-15 脂質ナノ粒子に用いるフッ化カチオン性脂質

Country Status (11)

Country Link
US (1) US20250092002A1 (cg-RX-API-DMAC7.html)
EP (2) EP4700017A2 (cg-RX-API-DMAC7.html)
JP (1) JP2024546950A (cg-RX-API-DMAC7.html)
KR (1) KR20240124983A (cg-RX-API-DMAC7.html)
CN (1) CN118647601A (cg-RX-API-DMAC7.html)
CA (1) CA3242406A1 (cg-RX-API-DMAC7.html)
DK (1) DK4448486T3 (cg-RX-API-DMAC7.html)
ES (1) ES3058144T3 (cg-RX-API-DMAC7.html)
FI (1) FI4448486T3 (cg-RX-API-DMAC7.html)
IL (1) IL313487A (cg-RX-API-DMAC7.html)
WO (1) WO2023114944A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108368028B (zh) 2015-10-28 2021-09-03 爱康泰生治疗公司 用于递送核酸的新型脂质和脂质纳米颗粒制剂
US12678515B2 (en) 2015-12-30 2026-07-14 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
US20250161227A1 (en) 2023-11-17 2025-05-22 Acuitas Therapeutics, Inc. Pegylated lipids
WO2025128696A1 (en) 2023-12-12 2025-06-19 Acuitas Therapeutics, Inc. Cationic lipid compounds for use in lipid nanoparticles
WO2025132122A1 (en) 2023-12-13 2025-06-26 Berlin Institute Of Health Methods of delivering therapeutics using lipid nanoparticles
WO2025126071A1 (en) 2023-12-14 2025-06-19 Pfizer Inc. Rna molecules
AU2025217182A1 (en) 2024-02-02 2026-08-06 Editas Medicine, Inc. MODIFIED GUIDE RNAs
WO2025174858A1 (en) 2024-02-15 2025-08-21 Acuitas Therapeutics, Inc. Cationic lipid compounds for use in lipid nanoparticles
TW202543583A (zh) 2024-03-01 2025-11-16 加拿大商阿奎特斯醫療公司 用於將治療劑包覆於脂質奈米顆粒中之材料及方法
WO2025186725A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Improved lnp formulations and uses thereof
US20250381150A1 (en) 2024-03-08 2025-12-18 Genzyme Corporation Lipid nanoparticles
WO2025213138A1 (en) 2024-04-05 2025-10-09 Editas Medicine, Inc. Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma
WO2025217264A1 (en) 2024-04-10 2025-10-16 Acuitas Therapeutics, Inc. Cationic lipid compounds for use in lipid nanoparticles
TW202604548A (zh) 2024-05-01 2026-02-01 加拿大商阿奎特斯醫療公司 使用脂質奈米顆粒進行肌內遞輸之方法
WO2025240833A1 (en) 2024-05-17 2025-11-20 Acuitas Therapeutics, Inc. Galnac lipid compounds for use in lipid nanoparticles
WO2026018181A1 (en) 2024-07-17 2026-01-22 Pfizer Inc. Immunogenic compositions and uses thereof
WO2026030375A2 (en) 2024-07-30 2026-02-05 Genzyme Corporation Lipid nanoparticles and methods of manufacture and use thereof
WO2026088119A1 (en) 2024-10-24 2026-04-30 Pfizer Inc. Lipidated tlr7/8 modulators as adjuvants and uses thereof
WO2026102260A1 (en) 2024-11-08 2026-05-15 Editas Medicine, Inc. Crispr-related methods and compositions targeting angiopoietin like 3 (angptl3)
WO2026142951A1 (en) 2024-12-23 2026-07-02 Genzyme Corporation Pharmaceutical system

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197553B1 (en) 1994-07-15 2001-03-06 Merck & Co., Inc. Method for large scale plasmid purification
EP1519714B1 (en) 2002-06-28 2010-10-20 Protiva Biotherapeutics Inc. Method and apparatus for producing liposomes
JP5639338B2 (ja) 2005-07-27 2014-12-10 プロチバ バイオセラピューティクス インコーポレイティッド リポソームの製造システムおよび製造方法
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
WO2013016058A1 (en) 2011-07-22 2013-01-31 Merck Sharp & Dohme Corp. Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery
US20140308304A1 (en) 2011-12-07 2014-10-16 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
CA2953341C (en) 2014-06-25 2023-01-24 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
HUE067372T2 (hu) 2015-06-29 2024-10-28 Acuitas Therapeutics Inc Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására
JP7461872B2 (ja) * 2017-08-17 2024-04-04 アクイタス セラピューティクス インコーポレイテッド 脂質ナノ粒子製剤における使用のための脂質
US20200093936A1 (en) * 2018-09-21 2020-03-26 The Trustees Of The University Of Pennsylvania Therapeutic Targeting of Lipid Nanoparticles

Similar Documents

Publication Publication Date Title
JP2024546951A5 (cg-RX-API-DMAC7.html)
JP2024546952A5 (cg-RX-API-DMAC7.html)
US5567765A (en) Physiologically acceptable emulsions containing perfluorocarbon ether hydrides and methods of use
JP2023535365A5 (cg-RX-API-DMAC7.html)
JP2020531422A5 (cg-RX-API-DMAC7.html)
US11001551B2 (en) Controlled release pharmaceutical formulations
JP2020517694A5 (cg-RX-API-DMAC7.html)
JP2018521052A5 (cg-RX-API-DMAC7.html)
JP2024543976A5 (cg-RX-API-DMAC7.html)
CA3200234A1 (en) Lipid nanoparticles for delivery of nucleic acids, and related methods of use
JP2006528700A5 (cg-RX-API-DMAC7.html)
JP2013056948A (ja) 安定なプロスタグランジン含有組成物
JP2020531418A5 (cg-RX-API-DMAC7.html)
JP2006528701A5 (cg-RX-API-DMAC7.html)
JP2018533573A5 (cg-RX-API-DMAC7.html)
CN1606446A (zh) 用单糖和二糖类化合物预防和治疗传染病和其他疾病的方法
JP2004508292A5 (cg-RX-API-DMAC7.html)
JP2011502174A5 (cg-RX-API-DMAC7.html)
HRP20240865T1 (hr) Lipidi i formulacije lipidnih nanočestica za isporuku nukleinskih kiselina
WO2011034192A1 (ja) ラタノプロストを含有する水性点眼剤、並びにラタノプロストの樹脂への吸着の抑制方法
JPH06504985A (ja) テロマー構造を有する両親媒性フッ素誘導体;調整および生物医学的適用
AU2006236534A1 (en) Methods of increasing natural killer cell activity for therapy
CN116924923A (zh) 阳离子脂质、脂质体及用途
JP2017534591A5 (cg-RX-API-DMAC7.html)
CN121889371A (zh) 脂质及其组合物